Rubicon Research Limited, incorporated in 1999, is a pharmaceutical company engaged in the development, manufacturing, and commercialisation of differentiated formulations. The company has built a portfolio of products approved by the US FDA, with a significant portion already commercialised in the US generic pharmaceutical market. Beyond the US, Rubicon has filed and registered products in several international markets, including the UK, Australia, Singapore, Saudi Arabia, and the UAE. The company also provides contract manufacturing services in select regions, supported by its manufacturing and R&D facilities in India and Canada. Its market position is strengthened by a diverse customer base, including major wholesalers, pharmacy chains, and managed care organisations.
Investors can apply for the Rubicon Research IPO through both online and offline channels. Online applications can be made via the ASBA (Application Supported by Blocked Amount) facility through net banking or UPI, using the investor’s demat account. Offline applications involve submitting a physical form along with payment instructions to the designated banks or brokers. Investors should ensure they meet the minimum subscription requirements and double-check their personal and demat details before submitting the application. Following allotment, shares will be credited directly to the demat account, and any unallotted funds will be released.
For more details, visit the Rubicon Research IPO page.
Rubicon Research IPO Details and Objectives
Details
| Information
|
IPO Date
| October 9, 2025 to October 13, 2025
|
Issue Size
| 2,84,02,040 shares
(aggregating up to ₹1,377.50 Cr)
|
Price Band
| ₹461 to ₹485 per share
|
Lot Size
| 30 shares
|
Listing At
| BSE NSE
|
Purpose of the IPO
Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company
Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes
Timeline of Rubicon Research IPO
Event
| Date
|
---|
IPO Open Date
| Thu, Oct 9, 2025
|
IPO Close Date
| Mon, Oct 13, 2025
|
Tentative Allotment
| Tue, Oct 14, 2025
|
Initiation of Refunds
| Wed, Oct 15, 2025
|
Credit of Shares to Demat
| Wed, Oct 15, 2025
|
Tentative Listing Date
| Thu, Oct 16, 2025
|
Cut-off time for UPI mandate confirmation
| 5 PM on Mon, Oct 13, 2025
|
Pricing & Lot Size of Rubicon Research IPO
Price Band for the IPO
Minimum Lot Size and Application Details
Application
| Lots
| Shares
| Amount
|
Retail (Min)
| 1
| 30
| ₹14,550
|
Retail (Max)
| 13
| 390
| ₹1,89,150
|
S-HNI (Min)
| 14
| 420
| ₹2,03,700
|
S-HNI (Max)
| 68
| 2,040
| ₹9,89,400
|
B-HNI (Min)
| 69
| 2,070
| ₹10,03,950
|
Rubicon Research IPO Application Process
The Rubicon Research IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Step 1: Login to Your Trading Platform
Access your trading account using the broker's app or website.
Step 2: Navigate to the IPO Section
Go to the IPO section to view active IPO listings.
Step 3: Select the Open IPO and Click Apply
Locate Rubicon Research IPO in the list of available IPOs and click the ‘Apply’ button.
Step 4: Enter the Quantity of Shares You Wish to Apply For
Specify the number of shares (minimum lot size: 30 shares) within the price band of ₹461 to ₹485 per share.
Step 5: Provide Your UPI ID
Enter your UPI ID for payment authorization and ensure sufficient funds in your bank account.
Step 6: Confirm the Application
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Step 7: Complete the Process and Wait for Allotment
Submit the application and monitor the allotment status to check if shares have been allocated to you.
Financial Health and Performance
Key Financial Metrics
Total Assets: Grew from ₹749.70 crore in FY23 to ₹1,647.60 crore as of June 2025.
Total income: Reached ₹356.95 crore in FY25.
Profit After Tax (PAT): Stood at ₹43.30 crore for June 2025.
Net Worth: Recorded at ₹593.67 crore in FY25.
Reserves and Surplus: Recorded at ₹397.50 crore (June 2025), growing steadily over the years.
EBITDA: Stood at ₹79.74 crore in June 2025.
Recent Performance and Growth Prospects
The company has demonstrated steady growth in its overall asset base over the recent years.
Total income has shown consistent improvement, reflecting expanding business operations and market presence.
Profitability has remained positive, indicating effective cost management and operational efficiency.
Net worth has increased steadily, highlighting the company’s strengthening financial position.
Reserves and surplus have grown over time, providing additional financial stability and support for future initiatives.
Operational performance, as reflected in EBITDA, suggests the company is maintaining stable earnings before interest, taxes, depreciation, and amortisation.
Overall, the company’s recent financial trends indicate a foundation for continued growth and expansion in domestic and international markets.
Investment Risks and Opportunities
Potential Risks of Investing in the IPO
The company’s reliance on approvals from regulatory authorities, such as the US FDA, may lead to delays or uncertainties in product launches.
A significant portion of revenue comes from a few major customers and wholesalers, creating potential exposure to changes in demand or contractual terms.
Opportunities and Growth Potential
Expansion into international markets, including the UK, Australia, Singapore, Saudi Arabia, and the UAE, offers potential for diversified revenue streams.
Ongoing product development, a steady pipeline of new formulations, and contract manufacturing services provide avenues for operational growth and market presence.
Key Performance Indicator (KPI)
KPI
| Values
|
ROE
| 29.02%
|
ROCE
| 26.45%
|
Debt/Equity
| 0.73
|
RoNW
| 29.02%
|
PAT Margin
| 10.37%
|
EBITDA Margin
| 20.67%
|
Rubicon Research IPO Registrar & Lead Managers
Registrar
| Lead Manager(s)
|
---|
MUFG Intime India Pvt.Ltd.
| Axis Capital Ltd.
|
Company Address of Rubicon Research Ltd
Rubicon Research Ltd. MedOne House, B-75, Road No. 33, Wagle Estate, Thane, Maharashtra, 400604
Phone: 022 61414000
Email: investors@rubicon.co.in
Website: https://www.rubicon.co.in/
Conclusion
Rubicon Research Limited operates as a pharmaceutical company with a presence in both domestic and international markets. Its business involves the development, manufacturing, and commercialisation of differentiated formulations, supported by regulatory approvals and a network of customers and distributors. The company maintains manufacturing and R&D facilities in multiple locations, which contribute to its ongoing operations and product development efforts.
The IPO application can be completed through online or offline channels, with steps involving selection of the IPO, submission of application details, and confirmation of payment through UPI or designated banks. Following the allotment process, shares are credited to the applicant’s demat account, and unallotted funds are returned.
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Rubicon Research IPO allotment status.